Department of Pediatrics, Duke University, Durham, North Carolina, USA.
Clin Pharmacol Ther. 2010 Jun;87(6):668-71. doi: 10.1038/clpt.2009.231. Epub 2010 Feb 3.
The incidence of cough in children receiving antihypertension therapy with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) is unknown. We analyzed patient-level data from eight randomized trials for the treatment of pediatric hypertension, six of them involving ACEis and two involving ARBs. The incidence of cough in children receiving ACEis (reported cough, 3.2%) was similar to that in children receiving ARBs (reported cough, 1.8%) (P = 0.34). Reports of cough were lower in children than in adults.
接受血管紧张素转换酶抑制剂（ACEI）或血管紧张素受体阻滞剂（ARB）降压治疗的儿童咳嗽发生率尚不清楚。我们分析了八项儿科高血压治疗随机试验的患者水平数据，其中六项涉及 ACEI，两项涉及 ARB。接受 ACEI 的儿童咳嗽发生率（报告咳嗽，3.2%）与接受 ARB 的儿童相似（报告咳嗽，1.8%）（P=0.34）。儿童报告的咳嗽发生率低于成人。
